Rapamycin, mTOR, and the Biology of Aging

Summary

Attia interviews Matt Kaeberlein on rapamycin's mechanism of action, the ITP (Interventions Testing Program) data showing lifespan extension in mice, and the current state of human evidence. They discuss dosing protocols, side effects, and why Attia uses rapamycin weekly in his own practice.

Key Takeaways

• 1

  Rapamycin inhibits mTORC1, the master regulator of cellular growth and autophagy

• 2

  ITP data: rapamycin extends median lifespan in mice by 10–23% even when started late in life

• 3

  Weekly pulsed dosing (5–8 mg) may preserve the longevity benefits while minimising immunosuppression

• 4

  Rapamycin's main risk at longevity doses is impaired wound healing and potential glucose dysregulation

• 5

  The Dog Aging Project is testing rapamycin in companion dogs — results expected 2025–2026

Molecules Discussed

Related Articles